• 1
    Abramson HA. The use of psychotherapy and alcoholism. Indianapolis, New York, Kansas City : Bobbs Merrill, 1967.
  • 2
    Passie T. Psycholytic and psychedelic therapy research: A complete international bibliography 1931–1995. Hannover : Laurentius Publishers, 1997.
  • 3
    Lee MA, Shlain B. Acid dreams, the CIA, LSD, and the sixties rebellion. New York : Grove Press, 1985.
  • 4
    Boskin J, Rosenstone RA. Protest in the sixties. Ann Am Acad Pol Soc Sci 1969;382:1219.
  • 5
    Hunter R. The storming of the mind. Toronto , Montreal: Doubleday , 1971.
  • 6
    SAMHSA. Available at:, 2006. Accessed 13 July 2008.
  • 7
    McGlothlin WH, Arnold DO. LSD revisited: A ten-year follow-up of medical LSD use. Arch Gen Psychiatry 1971;24:3549.
  • 8
    Cohen S. Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis 1960;130:3040.
  • 9
    Malleson N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 1971;118:229230.
  • 10
    Leuner H. Preface. In: PassieT. Psycholytic and psychedelic therapy research 1931–1995: A complete international bibliography. Hannover : Laurentius Publishers, 1997, pp. 57.
  • 11
    Gasser P. Die psycholytische Psychotherapie in der Schweiz von 1988–1993 Eine katamnestische Erhebung. Schweiz Arch Neurol Psychiatr 1997;147:5965.
  • 12
    Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology 2006;66:19201922.
  • 13
    Gasser P. LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. A phase-II, double-blind, placebo-controlled dose-response pilot study. Solothurn (Switzerland): Unpublished research protocol 2007. Available at: Accessed 13 July 2008.
  • 14
    Winkelman MJ, Roberts TB. Psychedelic medicine: New evidence for hallucinogenic substances as treatments. Westport , CT : Praeger, Greenwood, 2007.
  • 15
    Strassman RJ. Adverse reactions to psychedelic drugs: A review of the literature. J Nerv Ment Dis 1984;172:577595.
  • 16
    Henderson LA, Glass WJ. LSD: Still with us after all these years. New York : Macmillan, 1994.
  • 17
    Grof S. Realms of the human unconscious: Observations from LSD research. New York : Viking, 1975.
  • 18
    Leuner H. Die experimentelle Psychose. Berlin , Göttingen , Heidelberg: Springer , 1962.
  • 19
    Masters REL, Houston J. The varieties of psychedelic experience. New York : Holt, 1966.
  • 20
    Bradley RJ, Smythies JR. Structure-activity studies of lysergates and their interaction with biological molecules. In: SankarDVS, ed. LSD–A total study. New York : PJD Publications, 1975, pp. 141196.
  • 21
    Isbell H, Miner EJ, Logan CR. Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25). Psychopharmacol 1959;l:2028.
  • 22
    Rothlin E. Lysergic acid diethylamide and related substances. Ann NY Acad Sci 1957;66:668676.
  • 23
    Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacol 1995;118:401409.
  • 24
    Hoffman AJ, Nichols DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-Alkyl norlysergic acid N,N-diethylamide derivatives. J Med Chem 1985;28:12521255.
  • 25
    Nichols DE. Hallucinogens. Pharmacol Ther 2004;101:131181.
  • 26
    Farthing GW. The Psychology of Consciousness. Englewood Cliffs : Prentice Hall, 1992.
  • 27
    Katz MM, Waskow IE, Olsson J. Characterizing the psychological state produced by LSD. J Abnorm Psychol 1968;73:114.
  • 28
    Savage C. Variations in ego feeling induced by D-lysergic acid diethylamide (LSD-25). Psychoanal Rev 1955;1:116.
  • 29
    Hoffer A. LSD: A review of its present status. Clin Pharmacol Ther 1965;6:183255.
  • 30
    Stoll WA. Lysergsäurediäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiatr 1947;60:279323.
  • 31
    Grof S. The effects of LSD on chromosomes, genetic mutation, fetal development and malignancy. In: GrofS. LSD psychotherapy. Pomoma , CA : Hunter House, 1980, pp. 320347.
  • 32
    McGlothlin WH, Cohen S, McGlothlin MS. Long lasting effects of LSD on normals. Arch Gen Psychiatry 1967;17:521532.
  • 33
    Abramson HA, Jarvik ME, Kaufman MR, Kornetsky C, Levine A, Wagner M. Lysergic acid diethylamide (LSD-25): I. Physiological and perceptual response. J Psychol 1955;39:360.
  • 34
    Abramson HA, Waxenberg SE, Levine A, Kaufman MR, Kornetsky C. Lysergic acid diethylamide (LSD-25): XIII Effect on Bender-Gestalt test performance. J Psychol 1955;40:341349.
  • 35
    Kornetsky C. Relation of physiological and psychological effects of lysergic acid diethylamide. AMA Arch Neurol Psychiat 1957;77:657658.
  • 36
    Jarvik ME, Abramson AH, Hirsch MW. Lysergic acid diethylamide: Effects on attention and concentration. J Psychol 1955;39:373383.
  • 37
    Wapner S, Krus DM. Effects of lysergic acid diethylamide, and differences between normals and schizophrenics on the Stroop Color-Word Test. J Neuropsychiatry 1960;2:7681.
  • 38
    Jarvik ME, Abramson AH, Hirsch MW. Lysergic acid diethylamide: Effects upon recall and recognition of various stimuli. J Psychol 1955;39:443454.
  • 39
    Aronson H, Watermann CE. The effect of D-lysergic acid diethylamide (LSD-25) on learning and retention. J Clin Exp Psychopath 1962;23:1723.
  • 40
    Jarvik ME, Abramson AH, Hirsch MW, Ewals AT. Lysergic acid diethylamide: Effects on arithmetic test performance. J Psychol 1955;39:465473.
  • 41
    Sloane B, Lovett Doust JW. Psychophysiological investigations in experimental psychoses; results of the exhibition of d-lysergic acid diethylamide to psychiatric patients. J Ment Sci 1954;100:129144.
  • 42
    Isbell H, Belleville RE, Fraser HF, Wikler A, Logan CR. Studies on lysergic acid diethylamide: Effects in former morphine addicts and development of tolerance during chronic intoxication. AMA Arch Neurol Psychiatry 1956;76:468478.
  • 43
    Silverstein AB, Klee GD. Effects of lysergic acid diethylamide (LSD-25) on intellectual functions. AMA Arch Neurol Psychiatry 1958;80:477480.
  • 44
    Aronson H, Silverstein AB, Klee MD. Influence of LSD-25 on subjective time. Arch Gen Psychiatry 1959;1:469472.
  • 45
    Benda P, Orsini F. Étude expérimentale de l'estimation du temps sous LSD-25. Ann Med Psychol 1959;117:525533.
  • 46
    Lienert GA. Pharmakopsychologische Untersuchungen über den Abbau der geistigen Leistungsfähigkeit (Bericht über den 20 Kongress der Deutschen Gesellschaft für Psychologie), Berlin, Sept 26–29. 1955, Verlag für Psychologie, 1956;144147.
  • 47
    Lienert GA. Changes in the factor structure of intelligence tests produced by d-lysergic acid diethylamide (LSD). In: Bradley PB, ed. Neuro-Psychopharmacology. Amsterdam : Elsevier, 1959, pp. 461465.
  • 48
    Lienert GA. Über die Regression psychischer Funktionen als Folge pharmakologischer Belastung durch LSD und Alkohol. Med Exp Int J Exp Med 1961;5:203208.
  • 49
    Lienert GA. Mental age regression induced by lysergic acid diethylamide. J Psychol 1966;63:311.
  • 50
    Hintzen A. Die (Psycho)-Pharmakologie von Lysergsäurediäthylamid. Hannover : Hannover Medical School Dissertation, 2006.
  • 51
    Halpern JH, Pope HG Jr. Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 1999;53:247256.
  • 52
    Rothlin E, Cerletti A. Pharmacology of LSD-25. In: CholdenL, ed. Lysergic acid diethylamide and mescaline in experimental psychiatry. New York : Grune and Stratton, 1956, pp. 17.
  • 53
    Freedman DX. The psychopharmacology of hallucinogenic agents. Ann Rev Med 1969;20:409418.
  • 54
    Rothlin E. Metabolism of lysergic acid diethylamide. Nature 1956;178:14001401.
  • 55
    Evarts EV. Some effects of bufotenine and LSD on the monkey. AMA Arch Neurol Psychiatry 1956;75:4953.
  • 56
    Klock JC, Boerner U, Becker CE. Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases. West J Med 1974;120:183188.
  • 57
    Cohen MM, Marinello MJ, Back N. Chromosomal damage in human leukocytes induced by lysergic acid diethylamide. Science 1967;155:14171419.
  • 58
    Dishotsky NI, Loughman WD, Mogar RE, Lipscomb WR. LSD and genetic damage. Science 1971;172:431447.
  • 59
    Robinson JT, Chitham RG, Greenwood RM, Taylor JW. Chromosome aberrations and LSD. Br J Psychiatry 1974;125: 238244.
  • 60
    Smart RG, Bateman K. The chromosomal and teratogenic effects of lysergic acid diethylamide: A review of the current literature. Can Med Assoc J 1968;99:805810.
  • 61
    Leuner H. Halluzinogene. Psychische Grenzzustände in Forschung und Psychotherapie. Bern , Stuttgart , Wien : Huber, 1981.
  • 62
    Idanpään-Heikkilä JE, Schoolar JC. 14C-lysergide in early pregnancy. Lancet 1969;2:221.
  • 63
    Auerbach R, Rugowski JA. LSD: Effect on embryos. Science 1968;157:13251326.
  • 64
    Greiner TH, Burch NR, Edelberg R. Psychopathology and psychophysiology of minimal LSD-25 dosage. AMA Arch Neurol Psychiatry 1958;79:208210.
  • 65
    Salmoiraghi GC, McCubbin JW, Page IH. Effects of d-lysergic acid diethylamide and its brom derivative on cardiovascular responses to serotonin and on arterial pressure. J Pharmacol Exp Ther 1957;19:240247.
  • 66
    Tauberger G, Klimmer OR. Effects of high doses of d-lysergic acid diethylamide on the respiration, blood circulation and central sympathicus tone of cats. Arzneimittelforschung 1968;18:14891491.
  • 67
    DiMascio A, Greenblatt M, Hyde RW. A study of the effects of LSD: Physiologic and psychological changes and their interrelations. Am J Psychiatry 1957;114:309317.
  • 68
    Forrer G, Goldner R. Experimental physiological studies with LSD. AMA Arch Neurol Psychiatry 1951;65:581588.
  • 69
    Hollister LE. Pharmacology of LSD in man. In: Radouco-ThomasS, VilleneuveA, Radouco-ThomasC, eds. Pharmacology, toxicology and abuse of psychotominetics. Quebec : Les Presses de l'Université Laval, 1974, pp. 173183.
  • 70
    Liddell DW, Weil-Malherbe H. The effects of methedrine and of lysergic acid diethylamide on mental processes and on the blood adrenaline level. J Neurochem 1953;16:713.
  • 71
    Abramson HA, Jarvik ME, Hirsch MW. Lysergic acid diethylamide (LSD-25): X. Effects on reaction time to auditory and visual stimuli. J Psychol 1955;40:3946.
  • 72
    Belsanti R. Nuove ricerche in psichiatria sperimentale con la dietilamide dell'acido lisergico. Acta Neurol 1955;10:460.
  • 73
    Fischer R, Georgi F, Weber R. Psychophysical correlations VIII. Experimental tests in schizophrenia: Lysergic acid diethylamide and mescaline. Schweiz Med Wochenschr 1951;81:817819.
  • 74
    Manger WM, Schwarz BE, Barrs CW. Plasma and cerebrospinal fluid concentration of epinephrine and norepinephrine in certain psychiatric conditions. In: abstract of communication, 12th Inter Physiol Congress. Brussels , 1956, 610.
  • 75
    Sokoloff L, Perlin S, Kornetsky C, Kety SS. The effects of d-lysergic acid diethylamide on cerebral circulation and overall metabolism. Ann NY Acad Sci 1957;66:468477.
  • 76
    Pincus G, Hoagland H. Adrenal cortical responses to stress in normal and psychotic subjects. Am J Psychiatry 1950;106:651659.
  • 77
    Hollister LE, Moore FF. Increased plasma free fatty acids following psychotomimetic drugs. J Psychiat Res 1965;3:199203.
  • 78
    Messiha FS, Grof S. D-lysergic acid diethylamide (LSD)-effect on biogenic amines excretion in man. Biochem Pharmacol 1973;22:23522354.
  • 79
    Hollister LE, Hartman AM. Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures. Compr Psychiatry 1962;3:235242.
  • 80
    Muzio JN, Roffwarg HP, Kaufman E. Alterations in the nocturnal sleep cycle resulting from LSD. Electroencephalogr Clin Neurophysiol 1966;21:313324.
  • 81
    Torda C. Contribution to serotonin theory of dreaming (LSD infusion). NY State J Med 1968;68:11351138.
  • 82
    Bliss EL, Clark LD, West CD. Studies of sleep deprivation—Relationship to schizophrenia. AMA Arch Neur Psychiatry 1959;81:348359.
  • 83
    Safer DJ. The effect of LSD on sleep-deprived men. Psychopharmacol 1970;17:414424.
  • 84
    Meltzer HY, Fessler RG, Simonovic M, Doherty J, Fang VS. LSD: Evidence for stimulation of pituritary dopamine receptors. Psychopharmacol 1977;54:3944.
  • 85
    Collu R, Letarte J, Leboeuf G, Ducharme JR. Endocrine effects of chronic administration of psychoactive drugs to prepubertal male rats II: LSD. Can J Physiol Pharmacol 1975;53:10231026.
  • 86
    Meltzer HY, Simonovic M, Fang VS, Goode DJ. Neuroendocrine effects of psychotomimetic drugs. McLean Hosp J 1981;6:115137.
  • 87
    Rinkel M, Hyde RW, Solomon HC, Hoagland H. Experimental psychiatry. II. Clinical and physio-chemical observations in experimental psychosis. Am J Psychiatry 1955;111:881895.
  • 88
    Hoch PH. Studies in routes of administration and counteracting drugs. In: CholdenL, ed. Lysergic acid diethylamide and mescaline in experimental psychiatry. New York : Grune and Stratton, 1956, pp. 812.
  • 89
    Upshall DG, Wailling DG. The determination of LSD in human plasma following oral administration. Clin Chim Act 1972;36:6773.
  • 90
    Stoll A, Rutschmann J, Hofmann A. Über die Synthese von 14C-Diäthylamin und 14C-Lysergsäure-diäthylamid. Helv Chim Acta 1954;37:820824.
  • 91
    Stoll A, Rothlin E, Rutschmann J, Schalch WR. Distribution and fate of 14C-labeled lysergic acid diethylamide (LSD 25) in the animal body. Experientia 1955;11:396397.
  • 92
    Boyd ES, Rothlin E, Bonner JF, Slater JH, Hodge HC. Preliminary studies of the metabolism of LSD using radioactive carbonmarked molecules. J Nerv Ment Dis 1955;122:470471.
  • 93
    Boyd ES. The metabolism of LSD. Arch Int Pharmacodyn Ther 1959;120:292311.
  • 94
    Lanz U, Cerletti A, Rothlin E. Distribution of lysergic acid diethylamide in the organism. Helv Physiol Pharmacol Acta 1955;13:207216.
  • 95
    Freedman DX, Coquet CA. Regional and subcellular distribution of LSD and effects on 5-HT levels. Pharmacologist 1965;7:183.
  • 96
    Snyder SH, Reivich M. Regional localization of LSD in monkey brain. Nature 1966;209:10931095.
  • 97
    Axelrod J, Brady RO, Witkop B, Evarts EV. The distribution and metabolism of LSD. Ann NY Acad Sci 1957;66:435444.
  • 98
    Hoff H, Arnold OH. Allgemeine Gesichtspunkte zur Pharmakopsychiatrie. In: BradleyPB, ed. Neuro-Psychopharmacology. Amsterdam : Elsevier, 1959, pp. 326337.
  • 99
    Diab IM, Freedman DX, Roth LJ. [3H] lysergic acid diethylamide: Cellular autoradiographic localization in rat brain. Science 1971;173:10221024.
  • 100
    Wagner JG, Aghajanian GK, Bing OHL. Correlation of performance test scores with „tissue concentration” of lysergic acid diethylamide in human subjects. Clin Pharmacol Ther 1968;9:635638.
  • 101
    Metzler CM. A mathematical model for the pharmacokinetics of LSD effect. Clin Pharmacol Ther 1969;10:737740.
  • 102
    Aghajanian GK, Bing OH. Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin Pharmacol Ther 1964;5:611614.
  • 103
    Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. The fate of lysergic acid di[14C]ethylamide ([14C]LSD) in the rat, guinea pig and rhesus monkey and of [14C]iso-LSD in rat. Biochem Pharmacol 1979;28:30933101.
  • 104
    Freter K, Axelrod J, Witkop B. Biochemical and pharmacological studies with d- and l-5-hydroxytryptophan. J Am Chem Soc 1957;79:31113117.
  • 105
    Niwaguchi T, Inoue T, Sakai T. Studies on enzymatic dealkylation of d-lysergic acid diethylamide (LSD). Biochem Pharmacol 1974;23:10731078.
  • 106
    Klette KL, Anderson CJ, Poch GK, Nimrod AC, ElSohly MA. Metabolism of lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (O-H-LSD) in human liver microsomes and cryopreserved human hepatocytes. J Anal Toxicol 2000;24:550556.
  • 107
    Canezin J, Cailleux A, Turcant A, Le Bouil A, Harry P, Allain P. Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2001;765:1527.
  • 108
    Faed EM, McLeod WR. A urine screening test of lysergide. J Chromatogr Sci 1973;11:46.
  • 109
    Papac DI, Foltz RL. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. J Anal Toxicol 1990;14:189190.
  • 110
    Peel HW, Boynton AL. Analysis of LSD in urine using radioimmunoassay—Excretion and storage effects. Can Soc Forensic Sci J 1980;13:2328.
  • 111
    Van Bocxlaer JF, Clauwaert KM, Lambert WE, Deforce DL, Van Den Eeckhout EG, De Leenheer AP. Liquid chromatography-mass spectrometry in forensic toxicology. Mass Spectrom Rev 2000;19:165214.
  • 112
    McCarron MM, Walberg CB, Baselt RC. Confirmation of LSD intoxication by analysis of serum and urine. J Anal Toxicol 1990;14:165167.
  • 113
    Kerrigan S, Brooks DE. Immunochemical extraction and detection of LSD in whole blood. J Immunol Methods 1999;224:1118.
  • 114
    Paul BD, Mitchell JM, Burbage R, Moy M, Sroka R. Gas chromatographic-electron-impact mass fragmentometric determination of lysergic acid diethylamide in urine. J Chromatogr 1990;529:103112.
  • 115
    Taunton-Rigby A, Sher SE, Kelley PR. Lysergic acid diethylamide: Radioimmunoassay. Science 1973;181:165166.
  • 116
    Reuschel SA, Eades D, Foltz RL. Recent advances in chromatographic and mass spectrometric methods for determination of LSD and its metabolites in physiological specimens. J Chromatogr B Biomed Sci Appl 1999;733:145159.
  • 117
    Rohrich J, Zorntlein S, Becker J. Analysis of LSD in human body fluids and hair samples applying ImmunElute columns. Forensic Sci Int 2000;107:181190.
  • 118
    Nakahara Y, Kikura R, Takahashi K, Foltz RL, Mieczkowski T. Detection of LSD and metabolite in rat hair and human hair. J Anal Toxicol 1996;20:323329.
  • 119
    Arnold OH, Hofmann G, Leupold-Lowenthal H. Untersuchungen zum Schizophrenieproblem IV Mitteilung: Die Verteilung des C14-radioaktiven Lysergsäurediäthylamid (C14-LSD-25) im tierischen Organismus. Wien Z Nervenheilk 1958;15:1527.
  • 120
    Hertle F, Zipf KE, Broghammer H. Beobachtungen über Kreislaufverhalten, Muskeltonus und einige Kreislaufgrößen beim Menschen unter LSD-25-Einwirkung. Arch Psychiatr Nervenkr 1962;202:569591.
  • 121
    Anderson EW, Rawnsley K. Clinical studies of lysergic acid diethylamide. Monatsschr Psychiatr Neurol 1954;128:3855.
  • 122
    Bradley PB, Elkes C, Elkes J. On some effects of LSD in normal volunteers. J Physiol 1953;121:50.
  • 123
    Elkes J, Elkes C, Bradley PB. The effect of some drugs on the electrical activity of the brain and on behaviour. J Ment Sci 1954;100:125128.
  • 124
    Itil TM. Quantitative EEG and behavior changes after LSD and Ditran. In: KarczmarAG, KoellaWP, eds. Neurophysiological and behavioral aspects of psychotropic drugs. Springfield : Thomas, CC, III, 1969, pp. 7287.
  • 125
    Were PF. Electroencephalographic effects of LSD, and some psychiatric implications. J Neuropsychiatr 1964;5:516524.
  • 126
    Goldstein L, Murphree HB, Sugerman AA, Pfeiffer CC, Jenney EH. Quantitative electroencephalographic analysis of naturally occuring (schizophrenic) and drug-induced psychotic states in human males. Clin Pharmacol Ther 1963;4:1021.
  • 127
    Goldstein L, Stoltzfus NW. Psychoactive drug-induced changes of interhemispheric EEG amplitude relationships. Agents Actions 1973;3:124132.
  • 128
    Fink M, Itil T. Neurophysiology of phantastica: EEG and behavioral relations in man. In: Efron D, ed. Psychopharmacology: A review of progress 1957–1967. Washington , DC : US Government Printing Office, 1968, pp. 12311239.
  • 129
    Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar K A, Hermle L, Bull U, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]-FDG. Neuropsychopharmacol 1999;20:565581.
  • 130
    Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacol 1997;16:357372.
  • 131
    Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 2003;306:7383.
  • 132
    Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992;32:976991.
  • 133
    Vollenweider FX, Geyer MA. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull 2001;56:495507.
  • 134
    Wang J, Rao H, Wetmore GS, Furlan PM, Korczykowski M, Dinges DF, Detre JA. Perfusion functional MRI reveals cerebral blood flow pattern under psychological stress. Proc Natl Acad Sci USA 2005;102:1780417809.
  • 135
    Sinha R, Lacadie C, Skudlarski P, Wexler BE. Neural circuits underlying emotional distress in humans. Ann NY Acad Sci 2004;1032:254257.
  • 136
    Riba J, Romero S, Grasa E, Mena E, Carrio I, Barbanoj MJ. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology 2006;186:9398.
  • 137
    Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J Med Chem 2002;45:43444349.
  • 138
    Peroutka SJ, Sleight AJ, McCarthy BG, Pierce PA, Schmidt AW, Hekmatpanah CR. The clinical utility of pharmacological agents that act at serotonin receptors. J Neuropsychiatry Clin Neurosci 1989;1:253262.
  • 139
    Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacol 1998;136:409414.
  • 140
    Milburn CM, Peroutka SJ. Characterization of [3H]quipazine binding to 5-hydroxytryptamine3 receptors in rat brain membranes. J Neurochem 1989;52:17871792.
  • 141
    Gerald C, Adham N, Kao HT, Olsen MA, Laz TM, Schechter LE, Bard JA, Vaysse PJ, Hartig PR, Branchek TA, et al. The 5-HT4 receptor: Molecular cloning and pharmacological characterization of two splice variants. EMBO J 1995;14:28062815.
  • 142
    Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacol 1994;33:275317.
  • 143
    Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, Medhurst AD. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modelling. Mol Pharmacol 2003;64:12951308.
  • 144
    Eglen RM, Jasper JR, Chang DJ, Martin GR. The 5-HT7 receptor: Orphan found. Trends Pharmacol Sci 1997;18:104107.
  • 145
    U'prichard DC, Greenberg DA, Snyder SH. Binding characteristics of a radiolabelled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol Pharmacol 1977;13:454473.
  • 146
    Hüther G, Rüther E. Das serotonerge system. Bremen : Uni-Med Verlag, 2000.
  • 147
    Erlander MG, Lovenberg TW, Baron BM, De Lecea L, Danielson PE, Racke M, Slone AL, Siegel BW, Foye PE, Cannon K. Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc Natl Acad Sci USA 1993;90:34523456.
  • 148
    Lovenberg TW, Erlander MG, Baron BM, Racke M, Slone AL, Siegel BW, Craft CM, Burns JE, Danielson PE, Sutcliffe JG. Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci USA 1993;90:21842188.
  • 149
    Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320327.
  • 150
    Titeler M, Lyon RA, Glennon RA. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacol 1988;94:213216.
  • 151
    Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984;35:25052511.
  • 152
    Sanders-Bush E, Burris KD, Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine and partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharm Exp Ther 1988;246:924928.
  • 153
    Pierce PA, Peroutka SJ. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacol 1989;97:118122.
  • 154
    Martin-Ruiz R, Puig MV Celada P, Shapiro DA, Roth BL, Mengod G, Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin2A receptors through a glutamate-dependent mechanism. J Neurosci 2001;21:98569866.
  • 155
    Winter JC, Eckler JR, Rabin RA. Serotonergic/glutamatergic interactions: The effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacol 2004;172:233240.
  • 156
    Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behaviour. Neuron 2007;53:439452.
  • 157
    Nichols CD, Sanders-Bush EA. Single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacol 2002;26:634642.
  • 158
    Nichols CD, Garcia EE, Sanders-Bush E. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Brain Res Mol Brain Res 2003;111:182188.
  • 159
    Von Hungen K, Roberts S, Hill DF. LSD as an agonist and antagonist at central dopamine receptors. Nature 1974;252:588589.
  • 160
    Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacol 1995;118:401409.
  • 161
    Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man–A PET study with [11C]raclopride. Neuropsychopharmacol 1999;20:424433.
  • 162
    Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE. Re-evaluation of lisuride pharmacology: 5-HT1a receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacol 2002;164:93107.
  • 163
    Abramson HA, Jarvik ME, Govin MH, Hirsch MW. Lysergic acid diethylamide (LSD-25): XVIII. Tolerance development and is relationship to a theory of psychosis. J Psychol 1956;41:81105.
  • 164
    Cholden LS, Kurland A, Savage CU. Clinical reactions and tolerance to LSD in chronic schizophrenia. J Nerv Ment Dis 1955;122:211221.
  • 165
    Gresch PJ, Smith RL, Barrett RJ, Sanders-Bush E. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Neuropsychopharmacol 2005;30:16931702.
  • 166
    Cerletti A, Rothlin E. Role of 5-HT in mental diseases and its antagonism to lysergic acid derivates. Nature 1955;176:785786.
  • 167
    Abramson HA, Sklarofsky B, Baron MO, Freemont-Smith F. Lysergic acid diethylamide antagonists: II. Development of tolerance in man to LSD by prior administration of MLD. Arch Neurol Psychiatry 1958;79:201207.
  • 168
    Balestrieri A, Fontanari D. Acquired and cross-tolerance to mescaline, LSD and BOL. Arch Gen Psychiatry 1959;1:279282.
  • 169
    Isbell H, Wolbach AB, Wikler A, Miner EJ. Cross tolerance between LSD and psilocybin. Psychopharmacologia 1961;2:147159.
  • 170
    Balestrieri A. Studies on cross tolerance with LSD-25, UML-491 and JB-336. Psychopharmacol 1960;1:257259.
  • 171
    Rosenberg DE, Isbell H, Miner EJ, Logan CR. The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia 1964;13:217227.
  • 172
    Isbell H, Gorodetsky W, Jasinski D, Claussen U, Spulak FV, Korte F. Effects of delta-trans-tetrahydrocannabinol in man. Psychopharmacologia. 1967;11:187188.
  • 173
    Isbell H, Jasinski DR. A comparison of LSD-25 with (-)-delta-trans-tetrahydrocannabinol (THC) and attempted cross-tolerance between LSD and THC. Psychopharmacologia 1969;14:115123.
  • 174
    Wyatt RJ, Cannon EH, Stoff DM, Gillin JC. Interactions of hallucinogens at the clinical level. In: VesellES, BraudeMC, eds. Interactions of drugs of abuse. New York : NY Acad Sci, 1976, pp. 456486.
  • 175
    Murphree HB. Quantitative studies in humans on the antagonism of lysergic acid diethylamide by chlorpromazine and phenoxybenzamine. Clin Pharmacol Ther 1962;3:314320.
  • 176
    Hoch PH. Comments. Experimental psychiatry. Am J Psychiatry 1955;111:787790.
  • 177
    Giberti F, Gregoretti L. Prime esperienze di antagonismo psicofarmacologico. Sist Nerv 1955;4:301310.
  • 178
    Barnett BE. Diazepam treatment for LSD intoxication. Lancet 1971;2:270.
  • 179
    Levy RM. Diazepam for LSD intoxication. Lancet 1971;1:1297.
  • 180
    Bonson KR, Murphy DL. Alterations in response to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229233.
  • 181
    Heninger GR, Charney DS. Mechanism of action of antidepressant treatments: Implications for the etiology and treatment of depressive disorders. In: MeltzerHY, ed. Psychopharmacology: The third generation of progress. New York : Raven Press, 1987;pp. 535545.
  • 182
    Middendorf W. Personal communication. 2003.
  • 183
    Isbell H, Logan CR. Studies on the diethylamide of lysergic acid (LSD-25) II: Effects of chlorpromazine, azacyclonol and reserpine on the intensity of the LSD-reaction. AMA Arch Neurol Psychiatry 1957;77:350358.
  • 184
    Resnick O, Krus DM, Raskin M. LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci 1964;35:12071214.
  • 185
    Marecek P, Bakalar E, Zeman K. Attempt of blocking LSD intoxication with tranylcypromine. Act Nerv Super 1968;10:276277.
  • 186
    Grof S, Dytrych Z. Blocking of LSD reaction by premedication with Niamid. Act Nerv Super 1965;7:306.
  • 187
    Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacol 1996;14:425436.
  • 188
    Miller AI, Williams HL, Murphree HB. Niacin, niacinamide or atropine versus LSD model psychoses in human volunteers. J Pharmacol Exp Ther 1957;119:169170.
  • 189
    Clark LD, Bliss EL. Psychopharmacological studies of LSD intoxication—Effects of premedication with BOL, mescaline, atropine, amobarbital and chlorpromazine. AMA Arch Neurol Psychiatry 1957;78:653655.
  • 190
    Isbell H, Logan CR, Miner EJ. Studies on LSD III: Attempts to attenuate the LSD reaction in man by pretreatment with neuronal blocking agents. AMA Arch Neurol Psychiatry 1959;81:2027.
  • 191
    Abramson HA, Sklarofsk YB. Lysergic acid diethylamide (LSD-25) antagonists III: Modification of syndrome by prior administration of prednisone. Arch Gen Psychiatry 1960;2:8993.
  • 192
    Clark LD, Clark LS. The effects of cortisone on LSD intoxication in schizophrenic patients. J Nerv Ment Dis 1956;123:561562.
  • 193
    Krus DM, Wapner S, Bergen J, Freeman H. The influence of progesterone on behavioral changes induced by lysergic acid diethylamide (LSD-25) in normal males. Psychopharmacologia 1961;2:17784.
  • 194
    Balestrieri A. Amphetamine shock during LSD and mescaline psychosis. In: GarattiniS, GhettiV, eds. Psychotropic drugs. New York : Elsevier, 1957, p. 582 ff.
  • 195
    Kristensen K. LSD-behandling kombineret med parenteral Ritalinbehandling. Nord Psykiatr Tidsskr 1962;16:111116.
  • 196
    Marecek P, Bakalar E. Attempt to affect the course of LSD intoxication with ethyl alcohol. Act Nerv Super 1967;9:379380.
  • 197
    Vojtechovsky M, Skala J, Safratova V. Clinical picture of LSD psychosis following premedication with l-tyrosine and l-DOPA in chronic alcoholics. Act Nerv Super 1968;10:275276.
  • 198
    Holland D. Flashback-Phänomene als Nachwirkung von Halluzinogeneinnahme. Hannover : Hannover Medical School Dissertation, 2001.
  • 199
    Halpern JH, Pope HG Jr. Hallucinogen persisting perception disorder: What do we know after 50 years? Drug Alcohol Depend 2003;69:109119.